Judy Sebolt-Leopold and her team at MEKanistic Therapeutics developed a single molecule targeting two kinase enzymes that drive resistance to cancer therapies.
Antibodies that simultaneously target two distinct antigens overcome cancer therapy resistance by addressing antigenic diversity and diminished T cell action.